Toxicometabolomics-based cardiotoxicity evaluation of Thiazolidinedione exposure in human-derived cardiomyocytes
-
Published:2024-02-23
Issue:2
Volume:20
Page:
-
ISSN:1573-3890
-
Container-title:Metabolomics
-
language:en
-
Short-container-title:Metabolomics
Author:
Al Sultan Abdullah,Rattray Zahra,Rattray Nicholas J. W.
Abstract
Abstract
Introduction
Thiazolidinediones (TZDs), represented by pioglitazone and rosiglitazone, are a class of cost-effective oral antidiabetic agents posing a marginal hypoglycaemia risk. Nevertheless, observations of heart failure have hindered the clinical use of both therapies.
Objective
Since the mechanism of TZD-induced heart failure remains largely uncharacterised, this study aimed to explore the as-yet-unidentified mechanisms underpinning TZD cardiotoxicity using a toxicometabolomics approach.
Methods
The present investigation included an untargeted liquid chromatography–mass spectrometry-based toxicometabolomics pipeline, followed by multivariate statistics and pathway analyses to elucidate the mechanism(s)of TZD-induced cardiotoxicity using AC16 human cardiomyocytes as a model, and to identify the prognostic features associated with such effects.
Results
Acute administration of either TZD agent resulted in a significant modulation in carnitine content, reflecting potential disruption of the mitochondrial carnitine shuttle. Furthermore, perturbations were noted in purine metabolism and amino acid fingerprints, strongly conveying aberrations in cardiac energetics associated with TZD usage. Analysis of our findings also highlighted alterations in polyamine (spermine and spermidine) and amino acid (L-tyrosine and valine) metabolism, known modulators of cardiac hypertrophy, suggesting a potential link to TZD cardiotoxicity that necessitates further research. In addition, this comprehensive study identified two groupings – (i) valine and creatine, and (ii) L-tryptophan and L-methionine – that were significantly enriched in the above-mentioned mechanisms, emerging as potential fingerprint biomarkers for pioglitazone and rosiglitazone cardiotoxicity, respectively.
Conclusion
These findings demonstrate the utility of toxicometabolomics in elaborating on mechanisms of drug toxicity and identifying potential biomarkers, thus encouraging its application in the toxicological sciences. (245 words)
Funder
Kuwait University Engineering and Physical Sciences Research Council Medical Research Council Royal Society
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Association, A. D. (2023). Standards of care in diabetes—2023 abridged for primary care providers. Clinical Diabetes, 41(1), 4–31. 2. Bourgault, S., Choi, S., Buxbaum, J. N., Kelly, J. W., Price, J. L., & Reixach, N. (2011). Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochemical and Biophysical Research Communications, 410(4), 707–713. 3. Cabaton, N. J., Poupin, N., Canlet, C., Tremblay-Franco, M., Audebert, M., Cravedi, J. P., Riu, A., Jourdan, F., & Zalko, D. (2018). An untargeted metabolomics approach to investigate the metabolic modulations of HepG2 cells exposed to low doses of bisphenol A and 17β-estradiol. Frontiers in Endocrinology, 9, 571. 4. Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P., & Mirza, W. (2017). Clinical review of antidiabetic drugs: Implications for type 2 diabetes Mellitus Management. Front Endocrinol (Lausanne), 8, 6. 5. Dahabiyeh, L. A., Malkawi, A. K., Wang, X., Colak, D., Mujamammi, A. H., Sabi, E. M., Li, L., Dasouki, M., & Abdel Rahman, A. M. (2020). Dexamethasone-induced perturbations in tissue metabolomics revealed by chemical isotope labeling LC-MS analysis. Metabolites, 10(2), 42.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|